Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia

References

• Farnsworth WE. Estrogen in the etiopathogenesis of BPH. Prostate 1999;41:263–74
   PubMed Web of Science ®Google Scholar
• Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 2001;57:31–8
   PubMed Web of Science ®Google Scholar
• Wallner LP, Clemens JQ, Sarma AV. Prevalence of and risk factors for prostatitis in African American men: the Flint Men’s Health Study. Prostate 2009;69:24–32
   PubMed Web of Science ®Google Scholar
• Liao CH, Li HY, Chung SD, et al. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years. Aging Male 2012;15:28–33
   PubMed Web of Science ®Google Scholar
• Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146–9
   PubMed Web of Science ®Google Scholar
• Qian X, Yu G, Qian Y, et al. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate. Aging Male 2015;18:1–6
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM. Study 43203 Investigators, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male 2015;18:157–63
   PubMed Web of Science ®Google Scholar
• Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984–7
   PubMed Web of Science ®Google Scholar
• Trop-Pedersen S, Juul N, Jakobsen H. Transrectal prostatic ultrasonograpyh: equipment, normal findings, benign hyperplasia and cancer. Scand J Urol Nephrol Suppl 1988;107:19–25
   PubMedGoogle Scholar
• Bosch JL, Bohnen AM, Groeneveld FP, et al. Validity of three calipler-based transrectal ultrasound methods and digital rectal examination in the estimation of prostate volume and its changes with age: the Krimpen study. Prostate 2005;62:353–63
   PubMed Web of Science ®Google Scholar
• Trivedi MR, Choudhary BA. Digital rectal examination, transrectal ultrasound and prostate specific antigen as a triple assessment diagnostic tool for benign enlargement of prostate. Natl J Med Res 2015;5:244–8
   Google Scholar
• Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581–9
   PubMed Web of Science ®Google Scholar
• Hochberg DA, Armenakas NA, Fracchia JA. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate 2000;45:315–19
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481–7
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301–6
   PubMed Web of Science ®Google Scholar
• Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen study. Eur Urol 2004;46:753–9
   PubMed Web of Science ®Google Scholar
• Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostatic-specific antigen as predictors of acute urinary retention: combined experience from three large multinational placebo-controlled trials. Eur Urol 2000;38:563–8
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in man enrolled in the MTOPS trial. J Urol 2008;180:1030–2. Discussion 1032–3
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, Meehan AG. MTOPS Research Group, et al. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 2011;185:1369–73
   PubMed Web of Science ®Google Scholar
• Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309–15
   PubMed Web of Science ®Google Scholar
• Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398–405
   PubMed Web of Science ®Google Scholar
• Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007;51:1645–52
   PubMed Web of Science ®Google Scholar
• Choi H, Park JY, Shim JS, et al. Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in Korean population. Int Neurourol J 2013;17:73–7
   PubMed Web of Science ®Google Scholar
• Kayikci A, Cam K, Kacagan C, et al. Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms. Urology 2012;80:1088–92
   PubMed Web of Science ®Google Scholar
• Mao Q, Zheng X, Jia X, et al. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol 2009;41:761–6
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542–7
   PubMed Web of Science ®Google Scholar